Alkem Laboratories has signed a license agreement with Harvard University's Office of Technology Development (OTD) enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by
vascular disease. The license grants Alkem commercialization rights in the United States and India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
